Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
Status:
Unknown status
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety, tolerability and anti-tumor effects
of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with
castrate metastatic prostate cancer.